Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada
Testing supporting allergy diagnosis now accessible to more people in more communities
Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023
The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time
The strategic appointment is also critical to reinforcing Healthium’s market leadership, corporate governance and deep domain expertis
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
The partnership will capitalize on the combined capabilities of the two organizations
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
Subscribe To Our Newsletter & Stay Updated
